Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. Aerovate was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/07/20 | $72,600,000 | Series A |
Atlas Venture Cormorant Asset Management Osage University Partners RA Capital Management Sofinnova Partners  Surveyor Capital | undisclosed |
